Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea

Investopedia12-24 00:36

Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493279581?lang=en_US&edition=fundamental","thumbnail":"https://www.investopedia.com/thmb/MsjTDwT0fq0y4TVmTquZgWIYVHA=/4000x2667/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2126120280-94c8334d07474c6883f6bb568b95693f.jpg","is_english":true,"pubTime":"2024-12-24 00:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493279581","market":"hk","top_or_hot":-1,"title":"Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea","media":"Investopedia","content":"<div>\n<p>Key Takeaways\nEli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials ...</p>\n\n<a href=\"https://www.investopedia.com/lilly-rises-on-fda-approval-of-weight-loss-drug-zepbound-for-sleep-apnea-8765683\">Source Link</a>\n\n</div>\n","source":"investopedia_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-24 00:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investopedia.com/lilly-rises-on-fda-approval-of-weight-loss-drug-zepbound-for-sleep-apnea-8765683><strong>Investopedia</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Takeaways\nEli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials ...</p>\n\n<a href=\"https://www.investopedia.com/lilly-rises-on-fda-approval-of-weight-loss-drug-zepbound-for-sleep-apnea-8765683\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014906.USD","symbol_name":"大华全球优质成长基金Acc USD","start_time":0,"source_url":"https://www.investopedia.com/lilly-rises-on-fda-approval-of-weight-loss-drug-zepbound-for-sleep-apnea-8765683","article_id":"2493279581","we_media_id":null,"thumbnails":["https://www.investopedia.com/thmb/MsjTDwT0fq0y4TVmTquZgWIYVHA=/4000x2667/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2126120280-94c8334d07474c6883f6bb568b95693f.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493279581","pubTimestamp":1734971804,"columns":[],"sourceInfo":{"source_id":"investopedia_highlight","name":"Investopedia"},"weMediaInfo":null,"summary":"Eli Lilly's Zepbound has been approved by the Food and Drug Administration  as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials of the Lilly drug found that it helped reduce the number of breathing disruptions in an average night of sleep.Over a year, 50% of patients in one trial reported that their sleep apnea symptoms went away.Eli Lilly's  Zepbound has received Food and Drug Administration  approval as a treatment for obstructive sleep apnea for adults with obesity, the drugmaker announced late Friday.The approval comes after several trials earlier this year that showed the tirzepatide-based drug is five times more effective than a placebo at reducingbreathing disruptions caused by obstructive sleep apnea  and in 50% of cases, completely preventing them.\"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity,\" said Patrik Jonsson, president of Lil","collect":0,"end_time":0,"defaultTopTitle":"investopedia.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014906.USD":"大华全球优质成长基金Acc USD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SG9999001176.USD":"United Global Healthcare Acc USD","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LLY":"礼来","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","NVO.AU":"NOVO RESOURCES CORP-CDI","NVO":"诺和诺德","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","BK4532":"文艺复兴科技持仓","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","BK7007":"医疗保健设备","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4567":"ESG概念","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","RMD":"瑞思迈","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","RMD.AU":"Resmed DRC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4504":"桥水持仓","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC"},"translate_title":"FDA批准治疗睡眠呼吸暂停的减肥药Zepbound，礼来公司股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD.AU":1,"RMD":1,"NVO.AU":1,"NVO":1,"LLY":1},"content_text":"Key Takeaways\nEli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials of the Lilly drug found that it helped reduce the number of breathing disruptions in an average night of sleep.Over a year, 50% of patients in one trial reported that their sleep apnea symptoms went away.\n Eli Lilly's (LLY) Zepbound has received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea for adults with obesity, the drugmaker announced late Friday.\n\n\n The approval comes after several trials earlier this year that showed the tirzepatide-based drug is five times more effective than a placebo at reducing breathing disruptions caused by obstructive sleep apnea (OSA) and in 50% of cases, completely preventing them.\n\n\n  Zepbound Was Five Times Better at Reducing Breathing Disruptions  \n Lilly said its final trial evaluated sleep apnea and weight loss in those taking Zepbound, with some patients using a traditional \"positive airway pressure\" (PAP) mask while sleeping and others using no mask. Among those not using a sleep apnea mask, Zepbound was about five times more effective than a placebo at reducing the number of breathing disruptions per hour, the company said.\n\n\n \"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity,\" said Patrik Jonsson, president of Lilly USA.\n\n\n The trials found that adults on Zepbound alone lost an average of 45 pounds, or 18% of their body weight, while those adults on Zepbound combined with PAP therapy lost an average of 50 pounds or 20% of their body weight.\n\n\n \"Nearly half of clinical trial patients saw such improvements that they no longer had symptoms associated with OSA, marking a critical step forward in reducing the burden of this disease and its interconnected health challenges,\" Jonsson said.\n\n\n Zepbound got FDA approval to treat obesity and weight loss in November 2023, joining Eli Lilly's other tirzepatide-based drug, Mounjaro. The two drugs, along with Novo Nordisk's (NVO) Ozempic and Wegovy, have captured the majority of a surging weight-loss market that has grown substantially in recent years.\n\n\n Eli Lilly shares were up 1.6% at midday Monday, having gained about 34% on the year. Shares of ResMed (RMD), a medical device company that makes much of its revenue through the sale of sleep apnea masks, were 4% lower on Monday and have been negatively affected previously by the sleep apnea trials for Zepbound.\n\nDo you have a news tip for Investopedia reporters? Please email us at\ntips@investopedia.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493279581"}